IP Library › Granted Patent US 12,564,326
Granted Patent B2
US 12,564,326 · App. 18/488,357 · Granted Mar 3, 2026

Non-invasive bilirubin detection using induced photoreaction

Inventors: Aditya Kulkarni (Bengaluru, IN); Vamshi Kommareddy (Hyderabad, IN); Prasad Thapa (Bengaluru, IN); Gnanasekar Velusamy (Bengaluru, IN); Venugopal Manoharan (Narasangkuppam, IN)
Assignee: GE Precision Healthcare LLC
A61B5/0059A61B5/1455
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,564,326
App. No.
18/488,357
Granted
Mar 3, 2026
Kind
B2
Abstract

Techniques are disclosed for measuring a concentration of an analyte in a subject based on reflectance spectra obtained from the subject. The spectra are obtained while and/or before and/or after photoreactions are induced in the subject, where the photoreactions change the reflectivity of the subject. The rate of change of the reflectivity is correlated with the concentration of the analyte.

Claims (73)

1 . A method of determining a concentration of analyte in a subject, the method comprising:

collecting light reflected from a subject in response to light having a first wavelength, λ 1 , that is provided to the subject at a first time;

determining, based on the collected light, a first reflectivity of the subject in response to the light provided at the first time;

providing, over a period of time, light having a second wavelength, λ 2 , that corresponds to an absorption wavelength of the analyte, wherein absorption of the second wavelength by the analyte causes a change of the reflectivity of the subject;

collecting light reflected from the subject in response to light having the first wavelength, λ 1 , that is provided to the subject at a second time, wherein the second time is after the period of time;

determining, based on the collected light, a second reflectivity of the subject in response to the light provided at the second time;

determining the concentration of the analyte in the subject based on a difference between the second reflectivity and the first reflectivity.

2 . The method of claim 1 , wherein absorption of the light having the second wavelength by the analyte causes isomerization of the analyte in the subject.

3 . The method of claim 1 , wherein absorption of the light having the second wavelength by the analyte increases a solubility of the analyte in water.

4 . The method of claim 1 , further comprising:

determining a rate of change of a reflectivity of the subject during the period of time based on a difference between the second reflectivity and the first reflectivity; and

determining the concentration based on the rate of change of the reflectivity of the subject.

5 . The method of claim 1 , wherein providing the light having the first wavelength includes providing the light having the first wavelength transcutaneously to the subject and wherein providing the light having the second wavelength includes providing the light having the second wavelength transcutaneously to the subject.

6 . The method of claim 1 ,

wherein the second wavelength, λ 2 , is a wavelength in a range of 425 nm to 475 nm, and

wherein the analyte is bilirubin.

7 . The method of claim 1 ,

wherein the first wavelength, λ 1 , is a wavelength in a range of 480 nm to 520 nm, wherein the second wavelength, λ 2 , is a wavelength in a range of 425 nm to 475 nm, and

wherein the analyte is bilirubin.

8 . The method of claim 1 ,

wherein providing, at the first time, light having the first wavelength, λ 1 , to the subject, includes providing a continuous spectrum of light having a wavelength within a range of 480 nm and 520 nm to the subject at the first time,

wherein providing, at the second time, light having the first wavelength, λ 1 , to the subject, includes providing a continuous spectrum of light having a wavelength within a range of 480 nm and 520 nm to the subject at the second time,

wherein the second wavelength, λ 2 , is a wavelength in a range of 425 nm to 475 nm, and

wherein the analyte is bilirubin.

9 . The method of claim 1 ,

wherein providing, at a first time, light having the first wavelength, λ 1 , to the subject includes providing the light having the first wavelength to a first location of a surface of the subject,

wherein providing, at a second time, light having the first wavelength, λ 1 , to the subject includes providing the light having the first wavelength to the first location of the surface of the subject,

wherein collecting light reflected from the subject in response to the light provided to the subject at the first time and in response to the light provided to the subject at the first time includes collecting, at a plurality of second locations of the surface of the subject, the light reflected from the subject, wherein each of the second locations is a different distance from the first location, and further comprising:

determining concentrations of the analyte at different depths in the subject based on differences between the second reflectivity and the first reflectivity for the different distances between the first location and each of the second distances.

10 . The method of claim 1 ,

wherein determining the first reflectivity includes determining a first reflectivity of the subject at the first time,

wherein determining the second reflectivity includes determining a second reflectivity of the subject at the second time, and

wherein determining the concentration of the analyte in the subject includes determining the concentration based on a difference between the first reflectivity and the second reflectivity.

11 . The method of claim 1 , wherein a first spot size on the subject of the light having the first wavelength is greater than or equal to a second spot size on the subject of the light having the second wavelength.

12 . The method of claim 1 , wherein the light having the first wavelength, λ 1 , and the light having the second wavelength, λ 2 , is provided continuously to the subject and simultaneously is provided continuously to the subject for a time period of at least five seconds.

13 . A system for determining a concentration of analyte in a subject, the system comprising:

a first light source configured for providing light having a first wavelength, λ 1 , to the subject;

a second light source configured for providing light having a second wavelength, λ 2 , that corresponds to an absorption wavelength of the analyte, wherein absorption of the second wavelength by the analyte causes a decrease of a reflectivity of the subject in response to the providing of light having the first wavelength;

a detector configured for detecting light reflected from the subject in response to the light provided to the subject;

a computing device configured for:

controlling the first light source to provide the light having the first wavelength, λ 1 , to the subject at a first time and at a second time after the first time;

controlling the second light source to provide the light having the second wavelength, λ 2 , to the subject over a period of time, wherein at least a portion of the period of time is after the first time and before the second time;

determining, based on the detected light, a first reflectivity of light reflected from the subject in response to the light provided at the first time;

determining, based on the detected light, a second reflectivity of light reflected from the subject in response to the light provided at the second time; and

determining the concentration of the analyte in the subject based on a difference between the second reflectivity and the first reflectivity.

14 . The system of claim 13 , wherein absorption of the light having the second wavelength by the analyte causes isomerization of the analyte in the subject.

15 . The system of claim 13 , wherein absorption of the light having the second wavelength by the analyte increases a solubility of the analyte in water.

16 . The system of claim 13 , wherein the computing device is further configured for:

determining a rate of change of a reflectivity of the subject during the period of time based on a difference between the second reflectivity and the first reflectivity, and

determining the concentration based on the rate of change of the reflectivity of the subject.

17 . The system of claim 13 , wherein providing the light having the first wavelength includes providing the light having the first wavelength transcutaneously to the subject and wherein providing the light having the second wavelength includes providing the light having the second wavelength transcutaneously to the subject.

18 . The system of claim 13 ,

wherein the second wavelength, λ 2 , is a wavelength in a range of 425 nm to 475 nm, and

wherein the analyte is bilirubin.

19 . The system of claim 13 ,

wherein the first wavelength, λ 1 , is a wavelength in a range of 480 nm to 520 nm, wherein the second wavelength, λ 2 , is a wavelength in a range of 425 nm to 475 nm, and

wherein the analyte is bilirubin.

20 . The system of claim 13 ,

wherein providing, at the first time, light having the first wavelength, λ 1 , to the subject, includes providing a continuous spectrum of light having a wavelength within a range of 480 nm and 520 nm to the subject at the first time,

wherein providing, at the second time, light having the first wavelength, λ 1 , to the subject, includes providing a continuous spectrum of light having a wavelength within a range of 480 nm and 520 nm to the subject at the second time,

wherein the second wavelength, λ 2 , is a wavelength in a range of 425 nm to 475 nm, and

wherein the analyte is bilirubin.

21 . The system of claim 13 ,

wherein providing, at a first time, light having the first wavelength, λ 1 , to the subject includes providing the light having the first wavelength to a first location of a surface of the subject,

wherein providing, at a second time, light having the first wavelength, λ 1 , to the subject includes providing the light having the first wavelength to the first location of the surface of the subject,

wherein the detected light reflected from the subject in response to the light provided to the subject at the first time and at the second time is received from a plurality of second locations of the surface of the subject, wherein each of the second locations is a different distance from the first location, and

wherein the computing device is further configured for determining concentrations of the analyte at different depths in the subject based on differences between the second reflectivity and the first reflectivity for the different distances between the first location and each of the second distances.

22 . The system of claim 13 ,

wherein includes determining the first reflectivity determining a first reflectivity of the subject at the first time,

wherein determining the second reflectivity includes determining a second reflectivity of the subject at the second time, and

wherein determining the concentration of the analyte in the subject includes determining the concentration based on a difference between the first reflectivity and the second reflectivity.

23 . The system of claim 13 , wherein the first light source is configured for providing light having the first wavelength to the subject in a first spot size on the subject and wherein the second light source is configured for providing light having the second wavelength to the subject in a second spot size on the subject, wherein the first spot size is greater than or equal to the second spot size.

24 . The system of claim 13 , wherein the light having the first wavelength, λ 1 , and the light having the second wavelength, λ 2 , is provided continuously to the subject and simultaneously is provided continuously to the subject for a time period of at least five seconds.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2023
From: KULKARNI, ADITYA; KOMMAREDDY, VAMSHI; THAPA, PRASAD; VELUSAMY, GNANASEKAR; MANOHARAN, VENUGOPAL
To: GE PRECISION HEALTHCARE LLC
Reel/Frame 065252/0375 →
Continuity (3)
Provisional Application 63380888 · Oct 25, 2022
Related Publication 20240130619A1 · Apr 25, 2024
Related Publication 20240225449A9 · Jul 11, 2024
References Cited (159)
US 3569721A · Goldberg et al. · 1971 [cited by applicant]
US 3980696A · Anderson · 1976 [cited by applicant]
US 4029085A · Dewitt et al. · 1977 [cited by applicant]
US 4571383A · Takayama et al. · 1986 [cited by applicant]
US 4806485A · Birks et al. · 1989 [cited by applicant]
US 5259382A · Kronberg · 1993 [cited by applicant]
US 5262304A · Taniguchi · 1993 [cited by applicant]
US 5353790A · Jacques et al. · 1994 [cited by applicant]
US 5449622A · Yabe et al. · 1995 [cited by applicant]
US 5791345A · Ishihara et al. · 1998 [cited by applicant]
US 5792049A · Eppstein et al. · 1998 [cited by applicant]
US 5882301A · Yoshida · 1999 [cited by applicant]
US 5885224A · Yoshida · 1999 [cited by applicant]
US 5910421A · Small et al. · 1999 [cited by applicant]
US 5933226A · Yamanishi · 1999 [cited by applicant]
US 5983120A · Groner et al. · 1999 [cited by applicant]
US 6064898A · Aldrich · 2000 [cited by applicant]
US 6087182A · Jeng et al. · 2000 [cited by applicant]
US 6477394B2 · Rice et al. · 2002 [cited by applicant]
US 6522398B2 · Cadell et al. · 2003 [cited by applicant]
US 6553242B1 · Sarussi · 2003 [cited by applicant]
US 6596016B1 · Vreman et al. · 2003 [cited by applicant]
US 6671528B2 · Steuer et al. · 2003 [cited by applicant]
US 6943883B2 · Fodgaard · 2005 [cited by applicant]
US 6954661B2 · Cho et al. · 2005 [cited by applicant]
US 7039446B2 · Ruchti · 2006 [cited by examiner]
US 7171251B2 · Sarussi et al. · 2007 [cited by applicant]
US 7760340B2 · Hoshiko et al. · 2010 [cited by applicant]
US 7869033B2 · Masilamani et al. · 2011 [cited by applicant]
US 8054452B2 · Bado et al. · 2011 [cited by applicant]
US 8335550B2 · Segman · 2012 [cited by applicant]
US 9173603B2 · Molcho et al. · 2015 [cited by applicant]
US 9259486B2 · Koenig · 2016 [cited by applicant]
US 9279763B2 · Meijer et al. · 2016 [cited by applicant]
US 9366662B2 · Babson · 2016 [cited by applicant]
US 9535053B1 · Cafferty et al. · 2017 [cited by applicant]
US 9594076B2 · Sass · 2017 [cited by applicant]
US 9638686B1 · Cafferty et al. · 2017 [cited by applicant]
US 9933411B2 · Cafferty et al. · 2018 [cited by applicant]
US 10088468B2 · Cafferty et al. · 2018 [cited by applicant]
US 10463283B2 · Ferber et al. · 2019 [cited by applicant]
US 10512657B2 · Gedulin et al. · 2019 [cited by applicant]
US 10712347B2 · Strano et al. · 2020 [cited by applicant]
US 10732038B2 · Cafferty et al. · 2020 [cited by applicant]
US 20030198970A1 · Roberts · 2003 [cited by applicant]
US 20030202170A1 · Shepherd et al. · 2003 [cited by applicant]
US 20070026393A1 · Berlin et al. · 2007 [cited by applicant]
US 20070135335A1 · Collier et al. · 2007 [cited by applicant]
US 20070286856A1 · Brown et al. · 2007 [cited by applicant]
US 20080311107A1 · Bollinger et al. · 2008 [cited by applicant]
US 20090313707A1 · Combs et al. · 2009 [cited by applicant]
US 20120313268A1 · Bianchi et al. · 2012 [cited by applicant]
US 20130315913A1 · Zhang · 2013 [cited by applicant]
US 20150185233A1 · Raiker et al. · 2015 [cited by applicant]
US 20160047740A1 · Park et al. · 2016 [cited by applicant]
US 20160198992A1 · Sandrin et al. · 2016 [cited by applicant]
US 20170032099A1 · Cales et al. · 2017 [cited by applicant]
US 20170082603A1 · Cales et al. · 2017 [cited by applicant]
US 20170192021A1 · Sheppard et al. · 2017 [cited by applicant]
US 20180149635A1 · Abir · 2018 [cited by applicant]
US 20190025210A1 · Neijzen et al. · 2019 [cited by applicant]
US 20190079063A1 · Gilboa-Geffen et al. · 2019 [cited by applicant]
US 20190262629A1 · Broer et al. · 2019 [cited by applicant]
US 20190276872A1 · Lichte et al. · 2019 [cited by applicant]
US 20190343426A1 · Vartdal et al. · 2019 [cited by applicant]
US 20200088744A1 · Golmohammadi Ghane et al. · 2020 [cited by applicant]
US 20200163593A1 · Trau et al. · 2020 [cited by applicant]
CN 2109570U · 1992 [cited by applicant]
CN 1064152A · 1992 [cited by applicant]
CN 1158636A · 1997 [cited by applicant]
CN 1074790C · 2001 [cited by applicant]
CN 101221129A · 2008 [cited by applicant]
CN 101363869A · 2009 [cited by applicant]
CN 102107031A · 2011 [cited by applicant]
CN 101122605B · 2011 [cited by applicant]
CN 201899488U · 2011 [cited by applicant]
CN 101319993B · 2011 [cited by applicant]
CN 102525651A · 2012 [cited by applicant]
CN 102944683A · 2013 [cited by applicant]
CN 203303153U · 2013 [cited by applicant]
CN 103558171A · 2014 [cited by applicant]
CN 103961803A · 2014 [cited by applicant]
CN 104548379A · 2015 [cited by applicant]
CN 103300927B · 2015 [cited by applicant]
CN 103977772B · 2016 [cited by applicant]
CN 204931687U · 2016 [cited by applicant]
CN 105327336A · 2016 [cited by applicant]
CN 105362765A · 2016 [cited by applicant]
CN 105980833A · 2016 [cited by applicant]
CN 106202968A · 2016 [cited by applicant]
CN 205759157U · 2016 [cited by applicant]
CN 106295148A · 2017 [cited by applicant]
CN 107115593A · 2017 [cited by applicant]
CN 206534620U · 2017 [cited by applicant]
CN 206627519U · 2017 [cited by applicant]
CN 107951924A · 2018 [cited by applicant]
CN 107966410A · 2018 [cited by applicant]
CN 207232812U · 2018 [cited by applicant]
CN 108208266A · 2018 [cited by applicant]
CN 207623224U · 2018 [cited by applicant]
CN 104395729B · 2018 [cited by applicant]
CN 108615214A · 2018 [cited by applicant]
CN 109171757A · 2019 [cited by applicant]
CN 208448445U · 2019 [cited by applicant]
CN 109789312A · 2019 [cited by applicant]
CN 109925472A · 2019 [cited by applicant]
CN 109952099A · 2019 [cited by applicant]
CN 110192865A · 2019 [cited by applicant]
CN 110279699A · 2019 [cited by applicant]
CN 110621673A · 2019 [cited by applicant]
CN 110652413A · 2020 [cited by applicant]
CN 110711278A · 2020 [cited by applicant]
CN 110823880A · 2020 [cited by applicant]
CN 111004866A · 2020 [cited by applicant]
CN 111093494A · 2020 [cited by applicant]
DE 102017008631A1 · 2018 [cited by applicant]
EP 0071650A1 · 1983 [cited by applicant]
EP 0175330B1 · 1991 [cited by applicant]
EP 0679064A1 · 1995 [cited by applicant]
EP 0747002A1 · 1996 [cited by applicant]
EP 1169294A2 · 2002 [cited by applicant]
EP 1278452A1 · 2003 [cited by applicant]
EP 2458384A2 · 2012 [cited by applicant]
EP 2968230A2 · 2016 [cited by applicant]
EP 3296720A1 · 2018 [cited by applicant]
EP 3296739A1 · 2018 [cited by applicant]
EP 3377877A1 · 2018 [cited by applicant]
EP 3411689A1 · 2018 [cited by applicant]
EP 3438841A1 · 2019 [cited by applicant]
EP 3470839A1 · 2019 [cited by applicant]
EP 3513193A1 · 2019 [cited by applicant]
EP 3544504A1 · 2019 [cited by applicant]
EP 3591378A1 · 2020 [cited by applicant]
EP 3302449B1 · 2020 [cited by applicant]
GB 1250218A · 1971 [cited by applicant]
GB 1335483A · 1973 [cited by applicant]
GB 2046901A · 1980 [cited by applicant]
GB 2406638A · 2005 [cited by applicant]
WO 9639927A1 · 1996 [cited by applicant]
WO 9964627A2 · 1999 [cited by applicant]
WO 2005003351A1 · 2005 [cited by applicant]
WO 2005014634A1 · 2005 [cited by applicant]
WO 2009101538A2 · 2009 [cited by applicant]
WO 2012038930A1 · 2012 [cited by applicant]
WO 2013068518A1 · 2013 [cited by applicant]
WO 2014049131A1 · 2014 [cited by applicant]
WO 2016159050A1 · 2016 [cited by applicant]
WO 2016179981A1 · 2016 [cited by applicant]
WO 2017017676A1 · 2017 [cited by applicant]
WO 2017167030A1 · 2017 [cited by applicant]
WO 2019089768A1 · 2019 [cited by applicant]
WO 2019126470A1 · 2019 [cited by applicant]
WO 2019090158A9 · 2019 [cited by applicant]
WO 2019206929A2 · 2019 [cited by applicant]
WO 2020031196A1 · 2020 [cited by applicant]
WO 2020036565A2 · 2020 [cited by applicant]
WO 2020145899A1 · 2020 [cited by applicant]
“Dräger Jaundice Meter JM-105 Jaundice Management”, Dräger, 2013, 6 pages. [cited by applicant]
“Quick Reults With a Simple Touch—Philips Bilichek Noninvasive Bilirubin Assessment Tool”, Philips; Mother & Child Care; Jaundice Management, 2017, 8 Pages. [cited by applicant]